An interventional study of LIGHTER-MetS in Metabolic Syndrome (MetS) and Metabolic Syndrome, sponsored by National University Health System, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by National University Health System, Singapore · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Metabolic Syndrome with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Metabolic Syndrome · Singapore.
Among the 15 studies in Metabolic Syndrome with a site in Singapore, this one is one of 2 that started in 2026, is one of 7 with no phase, and was the 14th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →7 of the 15 studies in Metabolic Syndrome with a site in Singapore are open now. Recruiting first, the newest first:
National University Health System, Singapore · Sites in Singapore
Ages 21–70
Singapore Health Services · Sites in Singapore
Ages 21–65
National Heart Centre Singapore · Sites in Singapore
Ages 21–99 · Healthy volunteers
National University Hospital, Singapore · Sites in Singapore
Ages 40–70
Sengkang General Hospital · Sites in Singapore
Ages 21–99 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 316 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 135 across the 8 interventional studies, 97 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 8 most frequent:
National University Health System, Singapore is the lead sponsor of 42 studies on the registry; 12 are open to participants now.
National University Health System, Singapore has 2 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Metabolic Syndrome with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06363253Sengkang General HospitalPilot Study of the Human Metagenome in Metabolic Diseases | 2026-12-31 |
| NCT07410325National University Health System, SingaporeEffectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS) | 2027-01 |
| NCT07710274National University Health System, SingaporeEffectiveness of the Personalized Responses & Integrated Systems for Metabolism (PRISM) on Improving Insulin Resistance Among Adults With Metabolic Syndrome: A Pilot Study (PRISM-I) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Metabolic Syndrome with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effectiveness of the Lifestyle Intervention for Gentle, Healthy Transformation and Enhanced Weight Reduction-metabolic syndrome (LIGHTER-MetS) program on dietary self-regulation and cardiovascular risk among individuals with metabolic syndrome (MetS). The LIGHTER-MetS program, a community-based, grassroots-led initiative, integrates health coaching with the eTRIP© app to promote sustainable lifestyle changes focusing on diet, exercise, and emotion regulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
have 2 or more of the following to be classified as having metabolic syndrome:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The LIGHTER-MetS program includes community-based health coaching by the PI or a trained healthcare professional (e.g. nurse, physiotherapist etc.) at baseline visit and for 3 months following the baseline visit. Throughout the first 3 months, participants will also use the eTRIP© app to log meals, monitor physical activity, and receive personalized feedback. During the 3-month intervention period, there will be one-to-one slots for the health coach to follow up on participants' health plan.
Behavioral: LIGHTER-MetS
Participants will receive personalised health plans provided as part of usual care when they see a family physician. As part of the HealthierSG initiative, health plans are typically formulated to target early disease prevention and chronic condition management through history taking, physical examination, appropriate diagnostic testing, treatment, referrals and lifestyle modification goals and activity planning.
The LIGHTER-MetS program includes community-based health coaching by the PI or a trained healthcare professional (e.g. nurse, physiotherapist etc.) at baseline visit and for 3 months following the baseline visit. Throughout the first 3 months, participants will also use the eTRIP© app to log meals, monitor physical activity, and receive personalized feedback. During the 3-month intervention period, there will be one-to-one slots for the health coach to follow up on participants' health plan.
Self regulation of Eating Behaviour Questionnaire (SREBQ)
The Self-Regulation of Eating Behaviour Questionnaire (SREBQ) is a validated self-administered instrument used to assess individuals' self-regulation in relation to eating behavior. It evaluates the extent to which individuals monitor, control, and regulate their eating behaviors in everyday contexts. Higher scores indicate greater self-regulation of eating behavior.
Time frame: At baseline, 3, 6, and 12 months.
Cardiovascular Risk
Cardiovascular risk will be assessed via the ASCVD-risk calculator and the Singapore-modified Framingham Risk Score 2023 (SG-FRS-2023). Higher scores indicate a greater estimated cardiovascular risk.
Time frame: At baseline, 3, 6, and 12 months.
Weight
Time frame: At baseline, 3, 6, and 12 months.
Waist Circumference
Time frame: At baseline, 3, 6, and 12 months.
Blood Pressure
Both systolic and diastolic blood pressure will be assessed.
Time frame: At baseline, 3, 6, and 12 months.
Three Factor Eating Questionnaire (TFEQ)
The Three-Factor Eating Questionnaire (TFEQ) is a validated self-administered instrument used to assess eating-related behaviors. It measures three domains: cognitive restraint of eating, uncontrolled eating, and emotional eating. Higher scores indicate greater levels of the respective eating behavior.
Time frame: At baseline, 3, 6 and 12 month.
Consideration of Future Consequences Scale (CFCS-6)
The Consideration of Future Consequences Scale - 6 item (CFCS-6) is a validated self-administered questionnaire used to assess the extent to which individuals consider the potential future outcomes of their current behaviors. It evaluates the degree to which individuals weigh immediate versus future consequences when making decisions. Higher scores indicate greater consideration of future consequences.
Time frame: At baseline, 3, 6 and 12 month.
Self-Report Behavioural Automaticity Index (SRBAI)
The Self-Report Behavioural Automaticity Index (SRBAI) is a validated self-administered questionnaire used to assess the automaticity of behavior. It evaluates the extent to which a behavior is performed automatically, with little conscious thought or deliberation. Higher scores indicate greater behavioral automaticity.
Time frame: At baseline, 3, 6 and 12 month.
International Physical Activity Questionnaire Short-Form (IPAQ-SF)
The International Physical Activity Questionnaire - Short Form (IPAQ-SF) is a validated self-administered questionnaire used to assess self-reported physical activity levels. It captures the frequency and duration of walking, moderate-intensity activity, and vigorous-intensity activity performed over the past 7 days.
Time frame: At baseline, 3, 6 and 12 month.
Generalized Anxiety Disorder 2-item (GAD-2)
The Generalized Anxiety Disorder - 2 item (GAD-2) is a validated self-administered screening questionnaire used to assess the frequency of core anxiety symptoms over the past two weeks. Higher scores indicate greater anxiety symptom severity.
Time frame: At baseline, 3, 6 and 12 month.
Patient Health Questionnaire-2 (PHQ-2)
The Patient Health Questionnaire - 2 item (PHQ-2) is a validated self-administered screening questionnaire used to assess the frequency of depressive symptoms over the past two weeks. Higher scores indicate greater depressive symptom severity.
Time frame: At baseline, 3, 6 and 12 month.
Perceived Stress Scale (PSS-10)
The Perceived Stress Scale - 10 item (PSS-10) is a validated self-administered questionnaire used to assess perceived stress levels over the past month. It measures the extent to which individuals perceive situations in their lives as stressful. Higher scores indicate greater perceived stress.
Time frame: At baseline, 3, 6 and 12 month.
Euro Quality of life 5 Dimensions-5 Levels (EQ-5D-5L)
The EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) is a standardized self-administered instrument used to assess health-related quality of life. It measures five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with five response levels.
Time frame: At baseline, 3, 6 and 12 month.
Big Five Inventory - 44 item (BFI-44)
The Big Five Inventory - 44 item (BFI-44) is a validated self-administered questionnaire used to assess personality traits across five domains: openness, conscientiousness, extraversion, agreeableness, and neuroticism. Higher scores indicate greater expression of the respective personality traits.
Time frame: At baseline, 3, 6 and 12 month.
BMI
Measured using InBody 120.
Time frame: At baseline, 3, 6 and 12 month.
Percentage Body Fat
Measured using InBody 120.
Time frame: At baseline, 3, 6 and 12 month.
Body Fat Mass
Measured using InBody 120.
Time frame: At baseline, 3, 6 and 12 month.
Visceral Fat Level
Measured using InBody 120.
Time frame: At baseline, 3, 6 and 12 month.
Homeostatic Model Assessment of Insulin Resistance
Measured using (fasting blood insulin X fasting blood glucose)/22.5.
Time frame: At baseline, 3 and 12 months.
Fasting Blood Glucose (mmol/L)
Fasting blood glucose is a biochemical measure of blood glucose concentration after an overnight fast, measured using standard laboratory blood analysis. Higher values indicate poorer glycaemic control.
Time frame: At baseline, 3, 6 and 12 month.
Glycated haemoglobin (HbA1c) (%)
Glycated haemoglobin (HbA1c) reflects average blood glucose levels over the preceding two to three months and is measured using standard laboratory blood analysis. Higher values indicate poorer long-term glycaemic control.
Time frame: At baseline, 3, 6 and 12 month.
Triglycerides (mmol/L)
Triglycerides are a lipid biomarker measured using standard laboratory blood analysis to assess circulating triglyceride levels. Higher values indicate poorer lipid profiles and increased cardiometabolic risk.
Time frame: At baseline, 3, 6 and 12 month
High-density lipoprotein cholesterol (HDL-C) (mmol/L)
High-density lipoprotein cholesterol (HDL-C) is a lipid biomarker measured using standard laboratory blood analysis to assess protective cholesterol levels. Lower values indicate poorer lipid profiles and increased cardiometabolic risk.
Time frame: At baseline, 3, 6 and 12 month.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University Health System, Singapore